Dr Reddys

Dr Reddy's gets regulatory nod to sell generic version of Ozempic in India

Ozempic is also used off-label for weight loss due to its appetite-suppressing effects

Stocks to watch, Jan 22: Eternal, Dr Reddys, IndiGo, DLF, HPCL, PNB Housing

Stocks to watch on Thursday, January 22, 2026: KEI Industries, Bajaj Consumer Care, PNB Housing Finance and Jindal Stainless are among other key stocks to track today

Dr Reddy's Q3 PAT down 14% Y-o-Y on low Lenalidomide sales in US

Dr Reddy's Laboratories reported a sharp fall in December-quarter profit as declining Lenalidomide sales in the US weighed on earnings, even as India revenues and branded businesses remained resilient

Q3 results today: Dr Reddy's Lab, Eternal, Hindustan Petroleum on Jan 21

Q3FY26 company results: Firms including Bank of India, Jindal Stainless, PNB Housing Finance, and Tata Communications are also to release their October-December earnings reports today

Stocks to watch, Jan 21: Dr Reddys, Eternal, Persistent Sys, United Spirits

Stocks to watch today, Wednesday, January 21, 2026: Cyient DLM, Shoppers Stop, HDFC Bank, Tata Steel, and Vikram Solar are among other key stocks to track today.

Larger HC Bench clears way for export of semaglutide generics by Dr Reddy's

Novo Nordisk's appeal was listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Novo Nordisk challenges HC order permitting Dr Reddy's semaglutide exports

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Delhi HC refuses to halt order allowing Dr Reddy's to export Semaglutide

The Delhi High Court refused to stop an earlier order that lets Dr Reddy's make Semaglutide in India only for export, saying Novo Nordisk's patent challenge needs a full hearing before any decision

DRL semaglutide ruling may set precedent for generic makers: Experts

Ruling enables production for non-patented markets but bars India sales till 2026; experts say it may shape future drug access cases

Why did Dr Reddy's share rise over 2% in overall subdued market? Details

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Neuland, Lupin, Divi's lead domestic, CDMO surge amid US generics headwinds

Analysts noted that while US generics face margin headwinds, domestic formulations and CDMOs remain resilient. Biosimilars are also poised for growth through new launches and regulatory support.

Policymakers-industry partnership vital for healthcare delivery: Dr Reddy's

Dr Reddy's Laboratories on Monday said partnerships between policymakers and industry are vital to build a future-ready healthcare system that serves millions. Satish Reddy, the chairman of the Hyderabad-based drug major, joined industry leaders at the sixth Pre-Budget Consultation chaired by Union Finance Minister Nirmala Sitharaman in the national capital. He shared his perspective on the importance of risk-based innovation funding to strengthen India's pharmaceutical ecosystem and accelerate breakthroughs that improve patient access and affordability. "At Dr Reddy's, we believe that partnerships between policymakers and industry are vital to building a future-ready healthcare system that serves millions," Reddy said in a post shared by the drug firm on social networking platform LinkedIn.

Dr Reddy's gets EU nod for drug used to treat bone-weakening conditions

The European Commission's approval allows Dr Reddy's to market AVT03 across the European Union and European Economic Area for treating conditions that cause bone weakening

Motilal Oswal raises Nifty EPS, expects steady earnings momentum ahead

Earnings for the 151 MOFSL Universe companies rose 14 per cent year-on-year (Y-o-Y), above the brokerage's 9 per cent estimate.

New launch traction for Dr Reddy's key to offsetting price erosion

Given that price erosion in the North American market is expected to continue in the near term, some brokerages have cut their earnings estimates for the stock

Stock Market close: Sensex jumps 567 pts; Nifty at 25,966; PSU bank, realty stocks lead gains

Sensex Today | Stock Market close: In the broader market, the Nifty MidCap and the Nifty SmallCap index added 0.93 per cent and 0.82 per cent respectively

Brokerages see near-term upside in Dr Reddy's on Semaglutide, ex-US growth

Dr Reddy's Laboratories reported a consolidated Q2FY26 net profit of ₹1,437.2 crore, up 14 per cent Y-o-Y from ₹1,255.3 crore, with sequential growth largely flat.

Dr Reddy's Q2 net profit up 14% despite slump in North America biz

For H1FY26, profit after tax rose 8 per cent Y-o-Y and revenue grew 11 per cent, led by branded markets and contributions from the Nicotine Replacement Therapy (NRT) portfolio

Dr Reddy's Q2FY26 results: Profit up 14% at ₹1,437.2 cr, revenue jumps 10%

Dr Reddy's Ebitda for the quarter stood at ₹2,351.1 crore, up 3 per cent Y-o-Y and sequentially, with an Ebitda margin of 26.7 per cent

Q2 results today: Dr Reddy's Labs, ITC Hotels, NACL Industries on Oct 24

Aditya Birla Sun Life AMC, SBI Life Insurance Company, SBI Cards and Payment Services, India Radiators, and Sigachi Industries will also release their September quarter earnings reports today